On September 20, 2007, Imogai, Hassan Julien; Cid-Nunez, Jose Maria; Andres-Gil, Jose Ignacio; Trabanco-Suarez, Andres Avelino; Oyarzabal Santamarina, Julen; Dautzenberg, Frank Matthias; MacDonald, Gregor James; Pullan, Shirley Elizabeth; Luetjens, Robert Johannes; Duvey, Guillaume Albert Jacques; Nhem, Vanthea; Finn, Terry Patrick; Melikyan, Gagik published a patent.Safety of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was 1,4-Disubstituted 3-cyanopyridone derivatives and their use as positive allosteric modulators of mGlu2-receptors and their preparation. And the patent contained the following:
The invention relates to compounds, in particular pyridinone derivatives according to formula I wherein all radicals are defined in the application and claims. Compounds of formula I wherein V1 is a covalent bond and bivalent (un)saturated (un)branched C1-6 hydrocarbon radical; M1 is H, C3-7 cycloalkyl, aryl, alkylcarbonyl, alkyloxy, aryloxy, arylcarbonyl, etc.; L is a covalent bond, O, OCH2, OCH2CH2, OCH2CH2O, OCH2CH2OCH2, S, NH and derivatives, etc.; R2 and R3 are independently H, halo and alkyl; A is (un)substituted Ph, (un)substituted piperazinyl, (un)substituted piperidinyl, (un)substituted thienyl, (un)substituted furanyl, etc.; R4 is halo, CN, OH, oxo, formyl, ethanoyl, carboxyl, NO2, etc.; n is 0, 1, 2, and 3; and their pharmaceutically acceptable acid and addition base salts, stereochem. isomeric forms, N-oxides, and quaternary ammonium salts thereof, are claimed. The compounds according to the invention are pos. allosteric modulators of metabotropic receptors – sub-type 2 (“”mGluR2″”) which are useful for the treatment or prevention of neurol. and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their mGlu-2 receptor modulatory activity. From the assay, it was determined that compound II exhibited a pEC50 value of 6.2. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Safety of (6-(Trifluoromethyl)pyridin-3-yl)methanol
The Article related to disubstituted cyanopyridone preparation mglur2 modulator, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Safety of (6-(Trifluoromethyl)pyridin-3-yl)methanol
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts